{"id":33487,"date":"2025-05-20T14:00:00","date_gmt":"2025-05-20T12:00:00","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=33487"},"modified":"2025-09-10T08:37:22","modified_gmt":"2025-09-10T06:37:22","slug":"wstepne-wyniki-bohatera","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/pl\/wstepne-wyniki-bohatera\/","title":{"rendered":"Obiecuj\u0105ce wst\u0119pne wyniki badania HERO dla zespo\u0142u"},"content":{"rendered":"

Na pocz\u0105tku tego roku Alvin Luk wzi\u0105\u0142 udzia\u0142 w konkursie Medycyna CRISPR<\/em> w Kopenhadze, aby przedstawi\u0107 aktualne informacje na temat badania klinicznego HERO dotycz\u0105cego zespo\u0142u duplikacji genu MECP2. Jego prezentacja jest dost\u0119pna dla spo\u0142eczno\u015bci na YouTube.<\/p>\n\n\n\n

W tym filmie odkryjesz eksperymentaln\u0105 terapi\u0119 CRISPR-Cas13 firmy Huidagene, HG204<\/strong>i post\u0119py pierwszego leczonego dziecka, trzy miesi\u0105ce po otrzymaniu eksperymentalnego leku. Do zobaczenia na minuta 26:00<\/strong> aby wy\u015bwietli\u0107 obrazy pacjenta.<\/p>\n\n\n\n

Te wst\u0119pne wyniki s\u0105 bardzo zach\u0119caj\u0105ce i po raz kolejny sugeruj\u0105, \u017ce przywr\u00f3cenie poziomu bia\u0142ka MeCP2 mo\u017ce by\u0107 obiecuj\u0105c\u0105 strategi\u0105 walki z zespo\u0142em.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n<\/figure>\n\n\n\n

Drugie dziecko by\u0142o ju\u017c leczone HG204 i oczekuje si\u0119, \u017ce do sze\u015bciu pacjent\u00f3w zostanie kolejno w\u0142\u0105czonych do tego badania w Chinach.<\/p>\n\n\n\n

\n
Przejd\u017a do wideo<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du […]<\/p>","protected":false},"author":1,"featured_media":33493,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,201],"tags":[],"class_list":["post-33487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite","category-recherche-fr"],"yoast_head":"\nR\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2<\/title>\n<meta name=\"description\" content=\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/pl\/wstepne-wyniki-bohatera\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/pl\/wstepne-wyniki-bohatera\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T12:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T06:37:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuty\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome\",\"datePublished\":\"2025-05-20T12:00:00+00:00\",\"dateModified\":\"2025-09-10T06:37:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"},\"wordCount\":167,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"articleSection\":[\"Actualit\u00e9\",\"Recherche\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\",\"url\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\",\"name\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"datePublished\":\"2025-05-20T12:00:00+00:00\",\"dateModified\":\"2025-09-10T06:37:22+00:00\",\"description\":\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recherche\",\"item\":\"https:\/\/dupmecp2.eu\/category\/recherche-fr\/?lang=fr\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/pl\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Obiecuj\u0105ce wst\u0119pne wyniki badania HERO dla zespo\u0142u - DupMECP2","description":"Na pocz\u0105tku tego roku Alvin Luk wzi\u0105\u0142 udzia\u0142 w konferencji CRISPR Medicine w Kopenhadze, aby przedstawi\u0107 aktualne informacje na temat badania klinicznego HERO dotycz\u0105cego zespo\u0142u duplikacji genu MECP2. Jego prezentacja jest dost\u0119pna na YouTube dla spo\u0142eczno\u015bci.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/pl\/wstepne-wyniki-bohatera\/","og_locale":"pl_PL","og_type":"article","og_title":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2","og_description":"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.","og_url":"https:\/\/dupmecp2.eu\/pl\/wstepne-wyniki-bohatera\/","og_site_name":"DupMECP2","article_published_time":"2025-05-20T12:00:00+00:00","article_modified_time":"2025-09-10T06:37:22+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"Caroline","Szacowany czas czytania":"2 minuty"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome","datePublished":"2025-05-20T12:00:00+00:00","dateModified":"2025-09-10T06:37:22+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"},"wordCount":167,"commentCount":0,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","articleSection":["Actualit\u00e9","Recherche"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/","url":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/","name":"Obiecuj\u0105ce wst\u0119pne wyniki badania HERO dla zespo\u0142u - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","datePublished":"2025-05-20T12:00:00+00:00","dateModified":"2025-09-10T06:37:22+00:00","description":"Na pocz\u0105tku tego roku Alvin Luk wzi\u0105\u0142 udzia\u0142 w konferencji CRISPR Medicine w Kopenhadze, aby przedstawi\u0107 aktualne informacje na temat badania klinicznego HERO dotycz\u0105cego zespo\u0142u duplikacji genu MECP2. Jego prezentacja jest dost\u0119pna na YouTube dla spo\u0142eczno\u015bci.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"]}]},{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Recherche","item":"https:\/\/dupmecp2.eu\/category\/recherche-fr\/?lang=fr"},{"@type":"ListItem","position":3,"name":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"UE","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/pl\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts\/33487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/comments?post=33487"}],"version-history":[{"count":2,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts\/33487\/revisions"}],"predecessor-version":[{"id":33494,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts\/33487\/revisions\/33494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/media\/33493"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/media?parent=33487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/categories?post=33487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/tags?post=33487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}